Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• HER 2 Insertion or Amplification
• First Diagnosis and Treatment
• Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Locations
Other Locations
China
Yongchang Zhang
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Nong Yang, MD
yangnong0217@163.com
+8613055193557
Time Frame
Start Date: 2020-03-24
Estimated Completion Date: 2025-03-24
Participants
Target number of participants: 70
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital